Methods and systems of using exosomes for determining phenotypes
View Patent ↗Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.
1. A method of characterizing a cancer in a subject comprising:
(a) determining the presence or level of B7H3 protein and one or more tetraspanin protein biomarker from an exosome population isolated from a biological sample from said subject; and
(b) comparing said presence or levels of said proteins from said isolated exosome population to a reference, wherein elevated presence or levels as compared to said reference indicates that said subject may be predisposed to or afflicted with cancer, thereby characterizing said cancer.
2. The method of claim 1 , wherein the exosome population is isolated from a bodily fluid from said subject.
3. The method of claim 2 , wherein said bodily fluid is peripheral blood, serum, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, broncheoalveolar lavage fluid, semen, prostatic fluid, cowper's fluid or pre-ejaculatory fluid, female ejaculate, sweat, fecal matter, hair, tears, cyst fluid, pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates, blastocyl cavity fluid, or umbilical cord blood.
4. The method of claim 1 , wherein said exosome population comprises an exosome having a diameter of about 10 nm to about 800 nm.
5. The method of claim 1 , wherein said exosome population comprises an exosome having a diameter of about 30 nm to about 200 nm.
6. The method of claim 1 , wherein said exosome population is isolated from said biological sample with size exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunoabsorbent capture, affinity purification, affinity selection, microfluidic separation or a combination thereof.
7. The method of claim 1 , wherein the cancer is a prostate, lung, colon, breast, bladder, endometrial, liver, pancreatic, ovarian, esophageal or kidney cancer.
8. The method of claim 1 , wherein said one or more tetraspanin protein comprises CD9, CD63, CD81 or a combination thereof.
9. The method of claim 1 , wherein the cancer is a prostate cancer.
10. The method of claim 1 , wherein said one or more tetraspanin protein comprises CD9.
11. The method of claim 1 , wherein said determining comprises measuring an expression level, presence, absence, mutation, truncation, insertion, modification, sequence variation or molecular association of said proteins from said isolated exosome population.
12. The method of claim 2 , wherein said bodily fluid is blood, urine, serum or plasma.
13. The method of claim 1 , wherein said characterizing comprises one or more of determining an amount of exosomes, a temporal evaluation of a variation in exosome half-life, a temporal evaluation of circulating exosome half-life, a temporal evaluation of exosome metabolic half-life, or determining exosome activity.
14. The method of claim 9 , further comprising determining levels or presence of PCSA protein and/or PSMA protein from said isolated exosome population.
15. The method of claim 1 , wherein said determining the presence or level of said B7H3 protein and said one or more tetraspanin protein comprises using one or more binding agent that binds to at least one of said proteins from said exosome population.
16. The method of claim 15 , wherein said one or more binding agent is an antigen, DNA molecule, RNA molecule, antibody, antibody fragment, aptamer, peptoid, zDNA, peptide nucleic acid (PNA), locked nucleic acids (LNA), lectin, peptide, dendrimer or chemical compound.
17. The method of claim 1 , wherein said characterizing comprises a diagnosis, prognosis, determination of drug efficacy, monitoring the status of said subject's response or resistance to a treatment or selection of a treatment for said cancer.
18. The method of claim 1 , wherein said reference is derived from determining the presence or level of said B7H3 protein and one or more tetraspanin protein in said subject over a time course.
19. The method of claim 9 , wherein said one or more tetraspanin protein biomarker comprises CD9, CD63 or CD81 protein or a combination thereof.
20. The method of claim 9 , further comprising determining the presence or level of one or more prostate-specific biomarker from said exosome population.
21. The method of claim 20 , wherein said one or more prostate-specific biomarker comprises PCSA.
22. The method of claim 20 , wherein said one or more prostate-specific biomarker comprises PSMA.
23. The method of claim 20 , wherein said one or more prostate-specific biomarker comprises miR-141.
24. The method of claim 20 , wherein said one or more prostate-specific biomarker comprises TMPRSS2-ERG.
25. The method of claim 23 or 24 , wherein said biomarker is assessed by quantitative PCR, nucleic acid sequencing, hybridization assay or a combination thereof.
26. The method of claim 1 , further comprising determining a presence or level of at least one microRNA in said isolated exosome population.
27. A method of detecting prostate cancer in a patient comprising: detecting the levels of CD9 protein, PCSA protein, and B7H3 protein in isolated exosomes obtained from said patient, wherein elevated levels of CD9, PCSA, and B7H3 proteins in isolated exosomes obtained from said patient as compared to levels of CD9, PCSA, and B7H3 proteins in isolated exosomes obtained from a subject that does not have prostate cancer indicates said patient has prostate cancer.
28. The method of claim 26 , wherein said exosomes are isolated from said patient with size exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunoabsorbent capture, affinity purification, affinity selection, microfluidic separation or a combination thereof.
29. The method of claim 28 , wherein the affinity selection comprises contacting said exosomes with a binding agent that is specific for a protein biomarker selected from the group consisting of B7H3 protein, PCSA protein, CD9 protein, and a combination thereof.
30. The method of claim 29 , further comprising determining a presence or level of at least one microRNA in said isolated exosomes.
31. A method of detecting one or more candidate biomarker in a biological sample, comprising isolating exosomes from said biological sample and detecting the levels of CD9 protein and B7H3 protein associated with said isolated exosomes.
32. The method of claim 31 , wherein said exosomes are isolated from said sample with size exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunoabsorbent capture, affinity purification, affinity selection, microfluidic separation or a combination thereof.
33. The method of claim 32 , wherein the affinity selection comprises contacting said exosomes with a binding agent that is specific for a protein biomarker selected from the group consisting of B7H3 protein, CD9 protein, and a combination thereof.
34. The method of claim 33 , further comprising determining a presence or level of at least one microRNA in said isolated exosomes.